Glucobay Dosage/Direction for Use

Posology: Owing to the great individual variation of glucosidase activity in the intestinal mucosa, there is no fixed dosage regimen, and patients should be treated according to clinical response and tolerance of intestinal side-effects.
Adults: Treatment of NIDDM: The recommended initial dose is 50mg three times a day. However, some patients may benefit from more gradual initial dose titration to minimise gastrointestinal side-effects. This may be achieved by initiating treatment at 50mg once or twice a day, with subsequent titration to a three times a day regimen.
If after six to eight weeks' treatment patients show an inadequate clinical response, the dosage may be increased to 100mg three times a day. A further increase in dosage to a maximum of 200mg three times a day may occasionally be necessary.
If distressing complaints develop in spite of strict adherence to the diet, the dose should not be increased further and if necessary should be reduced according to the severity of the side-effects and the clinical judgment of the prescriber.
Glucobay is intended for continuous long-term treatment.
Prevention of NIDDM: The treatment shall begin with a daily dose of 50mg and be increased after 4-8 weeks to 3 x 100mg.
The recommended dose for patients with a body weight of 60 kg or less is 50 mg three times a day.
Elderly: No modification of the normal adult dosage regimen is necessary.
Paediatric population: The efficacy and safety of Glucobay in children and adolescents have not been established. Glucobay is not recommended for patients under the age of 18 years.
Method of administration: Glucobay tablets are taken orally and should be chewed with the first mouthful of food, or swallowed whole with a little liquid directly before the meal.